After COVID-19: Healthy lifestyle must be part of our ‘New Normal’ – MENAFN.COM

(MENAFN - Caribbean News Global) Arley Gill is an attorney at law and former culture minister of Grenada. He is also a former magistrate in the Commonwealth of Dominica

By Arley Gill

Few things compare to the hustle and bustle of Grenadian life. The lively banter between vendors and buyers in the market; the laughter of school children in schoolyards; the tug 'o' war battles between bus conductors and passengers; and the rhythmic sound of music blasting from windows of vehicles passing byeverywhere you turn, there is colour, there is music, there is niceness.

However, the essence of what makes us vibrant and colourful peoplethe sights and sounds of everyday living was abruptly halted by the invasion of COVID-19.

Forced to be at home for what may feel like forever, many of us are turning to food and drinks as a way to cope with a 24-hour lockdown. It is my view that as we settle into this 'new normal', a healthy lifestyle must be a personal and national priority if we are to truly rebound from, and also to resist in the future, public health threats such as COVID-19.

As a people, we are our nation's most valuable economic resource. And, regardless of the state of the economy after this global pandemic ends I caution that Grenada's economic recovery should not only be measured by the speed at which the tourism and construction sectors bounce back or by the employment rate.

What many nations are learning from the onset of the coronavirus is that the physical health of residents in any country, along with its healthcare infrastructure, are two of the most important factors in determining how well a nation responds to public health threats. Without a healthy workforce, there can be no real and meaningful economic recovery.

Of course, we are compelled to plan for the future, with or without the presence of the coronavirus. As we plan for the future, we must be concerned about jobs and livelihoods in Grenada. However, we should also be thinking about what our nation can learn from other nations both near and far about the impacts of public health threats, such as COVID-19, on vulnerable populations.

Let's take, for example, the United States of America.

In the US, Black Americans constitute only 13 percent of the population; yet, they are 30 percent of the people dying from COVID-19. America's death rate is similar for Black, Asian, Minority and Ethnic (BAME) individuals living in the United Kingdom. BAME residents are 14 percent of the UK population and 19 percent of the individuals dying of COVID-19.

Doctors on the frontlines of this global pandemics have observed an interesting phenomenon relative to COVID-19 and patients with underlying health conditions such as diabetes, cancer, high blood pressure, and asthma. Individuals, with weakened immune systems, are more likely to die from the virus. This observation should serve as a wake-up call for us in the Caribbean; and, specifically here in Grenada as we consider post-COVID-19 priorities, we must make a healthy lifestyle change a part of this 'new normal' in our country.

Eating too many salty foods, sugary drinks, and consuming foods with little or no nutritional value, are already wreaking havoc on vulnerable people around the world.

I am certain that each of us has a family member or friend in Grenada or elsewhere, living with diabetes or hypertension or both. In the aftermath of COVID-19, our government, for instance, can create ways to educate the public through culturally appropriate public service announcements; and, by developing a long-term plan to achieve food security not only in Grenada but also in the region.

In Grenada, we have more than enough fresh fruits and vegetables available for each person to consume. Therefore, it should be easy to eat healthy and prevent chronic diseases such as diabetes. But as we all know, this is not the case our people are already dying prematurely and in high numbers from preventable non-communicable diseases.

Eating local and staying healthy should be part of any new economic policy planning process. More importantly, and at the least, we must grow what we eat and eat what we grow. We once attempted to do so. It will be good for Grenadians, good for the economy and good for the planet.

Moving forward, let us come together as one family to encourage each other to eat well; consume alcohol in moderation and responsibly; exercise, and take care of each other. We should also find ways to promote and prioritize our small farmers and fisherfolks essential workers in the future fight against COVID-19.

A crucial part of Grenada's economic recovery cannot just focus on tourism and construction; to do so, will be to repeat errors made in the past. If COVID-19 taught us anything as small island states, it is that being able to feed our nation in times of crisis, is not only important but also quintessential to our survival.

I note with some regret, the fact that farmers and fisherfolks are not considered essential workers in this COVID-19 period. In my respectful view, they are the very essence of essential workers. They have to feed the doctors, nurses, police officers, patients, and everyone else. However, I guess that since we import so much of the food we consumewe do not appreciate the contributions of farmers and fisherfolks as we should.

With an eye on the future, I strongly propose that the ministry of agriculture and fisheries be subsumed as departments in a ministry of food security/production; thereby, shifting and intensifying the focus on farmers and fisherfolks. Food security and food production are areas the government should give greater attention. We need to transform the agricultural sector and move from a piecemeal approach to a more strategic approach.

This is a moment for new and revolutionary thinking on what economic recovery means in Grenada and the Caribbean region. Specifically, the government's efforts to restart Grenada's economy post-COVID-19 must include ideas that prioritize a healthy lifestyle that is tied to local food production and local consumption, and with food security as the ultimate goal.

We should not rely on yesterday's solutions to solve today and tomorrow's problems, especially as we figure out individually and collectively, what life will eventually look like after COVID-19.

MENAFN0505202002320000ID1100115792

Continued here:
After COVID-19: Healthy lifestyle must be part of our 'New Normal' - MENAFN.COM

The Scoop: Do we appreciate our healthy living community now that we have a national health crisis? – Greenville Journal

No matter where you fall on the political spectrum, you have to respect at the most recent press conference, Governor Henry McMaster mentioned exercise and mental health a dozen times. In his recent mandate exercise is permitted. We have all seen more people walking dogs, biking (all kinds) and running (all speeds!) in our neighborhoods.

Is a national pandemic actually going to make us appreciate the sidewalks, trails, bike lanes, local and state parks more than ever? (Remember weve paid for those sidewalks with our taxes so we should use them!)

What about the Swamp Rabbit Trail? The County portion of the Swamp Rabbit Trail remains open and busy! Ty Houck, Greenways Director for Greenville County is encouraged by the recent growth in the trail as long as people are following recommended standards. We ask that those who do use it during this time adhere to social distancing and other safety elements expressed by Governor McMaster and the CDC. Greenville Mayor Knox White said the first thing the Council wants to open is the city portion of the trail so it may be soon.

What about the bike businesses? Did you know bike shops are considered essential? Because bicycles are a method of transportation, they have remained open. Carolina Triathlon owner Randy Macdougal has been energized by people dusting off old bikes and bringing them in for tune-ups. Macdougal said their business is seeing a big uptick in repair work for people whose bikes are their sole means of transportation. These are not only the speedy spandex-wearers, but people of all ages and stages who are getting back to bike riding.

Macdougal has even seen a rise in sales in people getting new bikes for the first time as means of stress release and their desire to get out of the house and stay healthy. (Hint: What a great graduation gift for the class of 2020! ) West Pelzer Mayor Blake Sanders said the 8 miles of Doodle Trail from the City of Easley to Pickens is open and seeing a huge rise in walkers and bikers.

Supporting Small Business? Now more than ever, it is critical to shop small. Our local businesses sponsor the road race and the bike races downtown..not the global companies. Our neighborhood business owners are on the backs of Little League tee shirts. They are the ones who support our churches, schools and public safety. We want to remember to thank them with our support!

Josh Boggs, Sales Manager for Trek Bicycle Store located on Laurens Road in Greenville said we have changed more flat tires than probably any two day period in my 20 years in the bike business. Ok, thats a lot of tires.

What about running shoe stores? We have several locally owned running stores and they support the running community whole heartedly. (Just check out any road race and they are all there cheering on!) Local business owner of Greenville Running Company on Haywood Road, Jeff Milliman prides his store on custom fitting for running shoes but he has adjusted to curbside pickup. I think the new normal will be that people realize the least expensive way to stay fit, healthy and have a strong immune system will be running and exercise walking.

I remember running the Boston Marathon one year and an 8 year old held up a sign that said YOU WILL ALWAYS BE FASTER THAN YOUR SOFA. which made me laugh for miles

Keep moving! Stay safe! Stay healthy, Greenville.

Originally posted here:
The Scoop: Do we appreciate our healthy living community now that we have a national health crisis? - Greenville Journal

COVID-19 and Obesity: Reducing Risk with Healthy Habits – Medical Economics

As the COVID-19 crisis continues to unfold, flattening the curve has become the driving imperative for governments, public health officials, hospitals, health care workers, and citizens across the globe. Amid warnings from an official at the World Health Organization that the United States could become a pandemic epicenter, worst-case scenario projections at the time of writing forecast the country could experience a staggering 1.1 million deaths from the novel coronavirus. New guidelines from the Centers for Disease Control (CDC) calling for continued social distancing, frequent handwashing, and cloth face coverings in public are certainly effective habits to adopt to mitigate the spread of COVID-19. But what about our most vulnerable populations? Can healthy habits reduce their risk?

Obesity increases COVID-19 risk. Are Americans more vulnerable?

Early findings from hospitals in Wuhan indicate that 48 percent of COVID-19 patients had a comorbidity, with hypertension and diabetes being the most common. Given that more than one in four Americans live with obesity a complex disease associated with a number of chronic medical conditions including diabetes and hypertension it would be unwise to ignore the unique risks facing this rapidly growing segment of the countrys population.

More research is needed into the impact of COVID-19 on specific populations, such as patients with obesity. However, the emergence of H1N1 in 2009 offers some insight into what we might expect. During that pandemic, patients with obesity experienced greater severity of illness and patients with extreme obesity saw increased rates of hospitalization.

The continued spread of COVID-19 should raise flags of concern for health care professionals and citizens alike.

How can patients with obesity reduce their COVID-19 risk? Adopt healthy habits.

The CDCs guidelines are an excellent starting point for reducing COVID-19 risk during a global health crisis. However, the sheer volume of comorbidities and complications associated with obesity make the adoption of broad lifestyle changes within this vulnerable population both necessary and potentially life-saving during a widespread pandemic. After all, healthy lifestyle habits are associated with a significant decrease of mortality, regardless of BMI, but people with obesity experience the greatest benefit.

Key healthy habits that can help fortify patients with obesity against COVID-19 include:

Proper nutrition: Like other states of malnutrition, obesity causes inflammation, called adiposopathy, that reduces immune function. Research suggests that many foods, nutrients, and non-food nutrients modulate inflammation acutely and chronically.

Physical activity: Patients with obesity are often advised to eat less and move more to lose weight. Our understanding of obesity treatments is much more nuanced than this bit of conventional wisdom, but there is no denying the influence of physical activity on overall health and well-being just 60 minutes of moderate-to-vigorous exercise has a positive impact on the immune system.

Stress management: We now understand that the strong link between stress, obesity, and inflammation can inhibit the bodys natural defense system. Stress management techniques, such as exercise, meditation, and talk therapy can help patients living with obesity strengthen their immune systems.

Certainly, starting a new healthy habit is different than sticking to one. And research suggests that it can take at least two months, or 66 days on average, to form a new habit.

What can health care professionals do? Access obesity medicine resources.

We all owe a tremendous debt of gratitude to the dedicated health care professionals on the frontlines of this devastating pandemic. Health care professionals who are not currently stationed in hospitals or emergency departments may be wondering how they can help during a time of great uncertainty. Pursuing advanced knowledge of obesity medicine can empower health care professionals with tools and resources to better meet the needs of their patients within this vulnerable population.

The Obesity Medicine Association (OMA) offers a trove of resources including continuing medical education, American Board of Obesity Medicine (ABOM) exam preparation, Obesity Treatment Proficiency Badges, and The Obesity Algorithm, which offers comprehensive clinical guidance on the latest obesity management trends and evidence-based medical approaches to treatment. To become an OMA member, visit: https://obesitymedicine.org/join/.

The COVID-19 crisis has revealed the vulnerability of certain populations, including people living with obesity, to emerging public health crises. As we all look to do our part to flatten the curve, promoting healthy lifestyle habits alongside the CDC guidelines is an easy, proactive way for clinicians and other health care professionals to reduce coronavirus risk among our patients.

For more obesity medicine resources, visit: http://www.obesitymedicine.org.

Craig Primack, MD, FACP, FAAP, FOMA, Diplomate, American Board of Obesity Medicine, is the newly-elected President of the Obesity Medicine Association. He is board-certified in internal medicine, pediatrics and obesity medicine. Dr. Primack has been named Top Doctor by Phoenix Magazine since 2008. He is also the author of the book, Chasing Diets.

Excerpt from:
COVID-19 and Obesity: Reducing Risk with Healthy Habits - Medical Economics

Healthy living: The importance of staying hydrated – The South African

Many of us do not even realise we have become dehydrated, but your body knows when it needs more fluids and you become thirsty.

Mild dehydration symptoms can include, amongst other things, a headache, feelings of fatigue and a darker colour to urine. According to health experts, an average of two litres of water a day is beneficial. The amount of water necessary depends on a few factors like age, gender, level of activity, weight and even where you live. Living in a hot and humid environment makes you sweat more and therefore your body requires more hydration than average.

Our bodies need fluids to function properly, lets have a look at a few reasons.

Making sure you stay hydrated can also help to prevent certain health problems.

To stay hydrated doesnt mean you have to stick to water alone. You can also get fluids from beverages as well as from food itself. Here are some ideas that may help you with your daily intake.

Think about getting yourself a water bottle, preferably stainless steel or glass. You can carry the water bottle around with you and sip throughout the day. Dont just focus on water, you can drink tea and other juices. The main thing to remember with this is that you must take note of the amount of sugar consumed. Try to water down fruit juices a little and use the minimum amount of sugar in tea and coffee. Drink coffee in moderation.

Oatmeal is a great way to start the day, as it can be hydrating. Cooked oats absorb a lot of water and can help you feel full for longer. You can also add healthy foods like blueberries and other fruits to your porridge.

A tasty way you can stay hydrated is to make yourself smoothies. Simply combine some yoghurt and fruits with a blender. You can also add your chosen health shake powder or anything else that is healthy.

Winter is almost upon us and one of the best and nutritious ways to stay hydrated is to make yourself some soup, which can be eaten for lunch or dinner. In the summer months creating fruit popsicles is both a hydrating and cooling idea. You can simply add lemon slices or other fruits to a jug of water and pour yourself a glass ever so often. Try and use a smaller glass and drink more often. A larger glass can be difficult to finish but go ahead if this works better for you.

In conclusion, it will only benefit your overall health if you make sure you remain hydrated all year round.

This content has been created as part of our freelancer relief programme. We are supporting journalists and freelance writers impacted by the economic slowdown caused by #lockdownlife.

If you are a freelancer looking to contribute to The South African,read more here.

Visit link:
Healthy living: The importance of staying hydrated - The South African

How to Handle Health Insurance If You’re Now Unemployed Due to COVID-19 – Motley Fool

COVID-19 has unleashed two competing emergencies in the U.S. -- we face both a health crisis and an economic crisis. While stay-at-home mandates are slowing the spread of the virus, they're also causing millions of Americans to lose their jobs as businesses remain shuttered. Unfortunately, job loss usually also means loss of health insurance, which is problematic in the midst of a pandemic.

As states start to reopen and economic activity resumes, it's critical to maintain your health coverage. COVID-19 will continue to be a threat; the CDC is even predicting a stronger, second wave next winter. As well, the stress of losing your job and having to make ends meet in unconventional ways can also compromise your immune systemand increase your risk of getting sick.

Image source: Getty Images.

As to how you should maintain your health coverage, you do have three options. You can stay on your former employer's health plan through COBRA, you can purchase a plan on the healthcare marketplace, or you can join your spouse's workplace plan.

COBRA is a federal program that allows you and your family to continue on your employer's healthcare plan after you leave your job. Any employer who had more than 20 employees on its plan in the prior year is legally required to offer COBRA insurance to recently separated workers.

A major point of confusion about COBRA insurance is cost. You'd think that continuing on your employer's healthcare plan would cost you the same as it did while you were working. Unfortunately, that is not the case. The health insurance deductions taken from your pay only covered a portion of your premiums, usually less than half. If you elect to use COBRA, you are responsible for the entire premium plus a 2% fee.

Those premiums can be shockingly high. A study by the Kaiser Family Foundation reports that average annual individual healthcare premiums in 2019 were $7,188. Family coverage premiums were $20,576. Add 2% to those numbers, and that equates to monthly COBRA costs of $610 to $1,750.

You should receive notification in the mail detailing your options under COBRA within 30 to 45 days of your last day of work. If you choose to accept the coverage, it will be retroactive to that last day. You'll owe premiums back to that date, too.

Thankfully, the healthcare marketplace should have more affordable options. The marketplace was developed after the enactment of the Affordable Care Act in 2010to provide a range of health insurance options for individuals, families, and small businesses. Normally, you can only enroll in a marketplace plan between November 1 and December 15 of each year. But leaving your job, voluntarily or otherwise, qualifies you for a special enrollment period. That special enrollment period lasts for 60 days from the date you parted ways with your employer.

You can preview plans and estimated premiums by providing your zip code, along with some demographic and financial information. In my zip code, full-priced plans for an individual aged 35 have monthly premiums ranging from $335 to $610. The lower-priced plans have deductibles as high as $8,150 and coinsurance as high as 50%. Coinsurance is the portion of the bill you're responsible for after you reach your deductible.

Don't write off those premiums as too high, however. Your income may qualify you for lower rates. When you apply, you'll also find out if you're eligible for free or low-cost Medicaid coverage.

Employer plans should offer an enrollment period of at least 30 days for spouses who've lost coverage. If you're married and your spouse works, reach out to your spouse's plan administrator for a cost estimate and the enrollment deadline. You might need to supply some documentation of your marriage and job loss to your spouse's employer. But it'll be worth the paperwork. Of your three coverage options, this one should be the cheapest.

Keeping your health insurance in force is an important self-care step, but there are other actions you can take, too. For example:

These healthy living habits can help minimize your out-of-pocket healthcare expenses. Unfortunately, there isn't much to be done about the cost of healthcare premiums. Enrolling in your spouse's plan is the cheapest option, while COBRA will be the most expensive. The healthcare marketplace should have mid-range options, although the deductibles and coinsurance may be less appealing.

Whatever you do, don't ignore the issue of health insurance. Enrollment periods for COBRA, the marketplace, and spousal plans usually end within 30 to 90 days after your last day of work. If those deadlines pass, you'll have to find a private healthcare plan, at least until the marketplace enrollment period opens again in November.

Read more:
How to Handle Health Insurance If You're Now Unemployed Due to COVID-19 - Motley Fool

Latest Study explores the Testosterone Replacement Therapy Market Witness Highest Growth in near future – AlgosOnline

The ' Testosterone Replacement Therapy market' research report now available with Market Study Report, LLC, is a compilation of pivotal insights pertaining to market size, competitive spectrum, geographical outlook, contender share, and consumption trends of this industry. The report also highlights the key drivers and challenges influencing the revenue graph of this vertical along with strategies adopted by distinguished players to enhance their footprints in the Testosterone Replacement Therapy market.

Request a sample Report of Testosterone Replacement Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2430747?utm_source=algosonline.com&utm_medium=sp

The latest report on the Testosterone Replacement Therapy market contains a detailed analysis of this marketplace and entails information about various industry segmentations. According to the report, the market is presumed to amass substantial revenue by the end of the forecast duration while expanding at decent growth rate.

Details regarding the industry size, remuneration potential, and volume share are compiled in the report. It further lists out the drivers and challenges that will impact the growth of Testosterone Replacement Therapy market during the estimated timeframe.

The Testosterone Replacement Therapy market with respect to the geographical terrain:

Ask for Discount on Testosterone Replacement Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2430747?utm_source=algosonline.com&utm_medium=sp

Additional highlights from the Testosterone Replacement Therapy market report are enlisted below:

Table of Contents:

Executive Summary: It includes key trends of the Testosterone Replacement Therapy market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the Testosterone Replacement Therapy market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Testosterone Replacement Therapy market.

Market Segments: This part of the report discusses about product type and application segments of the Testosterone Replacement Therapy market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

For More Details On this Report: https://www.marketstudyreport.com/reports/global-testosterone-replacement-therapy-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Testosterone Replacement Therapy Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: Testosterone Replacement Therapy Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Related Reports:

1. Global Type 2 Diabetes Medication Market 2020 by Company, Regions, Type and Application, Forecast to 2025The Type 2 Diabetes Medication Market Report offer the complete scenario of the industry and valuation of upcoming Trends for future market. It also gives the analytic of enduring growth factor, trends and statistic of Type 2 Diabetes Medication Market industry. The Type 2 Diabetes Medication Market has been outlined by overall information and analysis.Read More: https://www.marketstudyreport.com/reports/global-type-2-diabetes-medication-market-2020-by-company-regions-type-and-application-forecast-to-2025

2. Global Rizatriptan Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Rizatriptan Market report starts from illustration of Industry Chain structure, and portrays industry condition, at that point investigations advertise size and figure of Rizatriptan by item, district and application, likewise, this report presents showcase rivalry circumstance among the merchants profile, plus, advertise value examination and esteem chain highlights are canvassed in this report.Read More: https://www.marketstudyreport.com/reports/global-rizatriptan-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Related Reports: https://www.marketwatch.com/press-release/sterile-injectables-market-size---detailed-analysis-of-current-industry-figures-with-forecasts-growth-by-2025-2020-05-04

Related Reports: https://www.marketwatch.com/press-release/at-139-cagr-devops-tools-market-size-set-to-register-59498-million-usd-by-2025-2020-05-05

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Read more from the original source:
Latest Study explores the Testosterone Replacement Therapy Market Witness Highest Growth in near future - AlgosOnline

District Courts In New Jersey And New York Dismiss Securities Class Actions Against Life Science Companies Emphasizing the High Pleading Bar With…

The United States District Courts for the District of New Jersey and the Southern District of New York recently dismissed putative securities class action complaints filed against life science companies in Smith v. Antares Pharma, Inc., et al. and Schaffer v. Nabriva Therapeutics PLC, et al.[1] The decisions make clear that the duty to disclose, imposed on life science companies by the federal securities laws, does not cover all conceivable information investors may find or consider relevant. Moreover, both courts held life science companies are not prohibited from expressing optimism about the prospects of FDA approval for products simply because of less-than-positive feedback from the regulator during the review process. The decisions, and their implications, are discussed below.

Antares Pharma Complaint

On December 21, 2016, Antares Pharma, Inc. (Antares) announced it submitted a New Drug Application (NDA) with respect to Phase 3 clinical studies, conducted in 2014 and 2015, for a testosterone replacement therapy (TRT) drug called QuickShot Testosterone which is currently marketed as Xyosted. Its stock price increased with the announcement. In October 2017, after Antares announced an October 11 FDA letter identifying deficiencies with the NDA, its common stock fell 37.80%. One week later, the FDA issued a Complete Response Letter (CRL) that rejected the NDA and identified clinically meaningful increases in blood pressure and incidents of depression and suicide. On January 11, 2018, Antares disclosed a 12.7% rate of hypertension observed in one of its Phase 3 studies.

Antares submitted a revised NDA in April 2018, which was approved by the FDA on October 1, 2018 with a black boxed warning for blood pressure increases, as well as warnings for risks of depression and suicide. Plaintiff contends Antaress stock price decreased 3% [o]n the heels of the revelation of approval with the requirement of a black box warning and risk of depression and suicide.

Nabriva Therapeutics Complaint

During the class period, Nabriva Therapeutics PLC (Nabriva) had only two products being considered by the FDA for marketing approval; it was not generating revenues from product sales, and did not expect to, unless one of the two drug candidates received approval. In October 2018, Nabriva filed a NDA with respect to Contepo, a drug intended to treat complicated urinary tract infections; this prompted FDA review, which would conclude with a final decision from the FDA by April 30, 2019. On December 14, 2018, the FDA issued a Form 483 letter[2] identifying inspectional observations it made, after visiting the manufacturing plant, that suggested the plant was not in compliance with applicable standards. Nabriva made several statements regarding the Contepo NDA during the class period, none of which mentioned the FDAs Form 483. Ultimately, the FDA did not approve the Contepo NDA. Instead, it issued a CRL withholding approval based substantially on the issues identified in the Form 483 letter. Upon this news, Nabrivas share price declined over 27%.

On August 16, 2019, Nabriva announced it would resubmit the Contepo NDA after rectifying the issues identified in the CRL. Because resubmission would retrigger a six-month review cycle, the FDA would likely not approve Contepo in 2019. Plaintiff alleged statements Nabriva made during the class period were misleading because they led investors to believe the FDA would approve the Contepo NDA in 2019, even though the Form 483 demonstrated that approval would be delayed beyond that year.

Dismissals of the Complaints

In both cases, the complaints were dismissed in their entireties, emphasizing that a life science companys duty to disclose is not unlimited and that it is not enough to plead that an optimistic forward-looking statement regarding approval prospects or timing of approval turns out to be incorrect.

Duty to Disclose

The Supreme Court has made clear that Section 10(b) of the Securities Exchange Act and Rule 10b5 do not create an affirmative duty to disclose any and all material information. Disclosure is required . . . only when necessary to make . . . statements made, in the light of the circumstances under which they were made, not misleading.[3]

In this vein, the Antares decision rejected plaintiffs argument that the failure to disclose the exact statistical risk of any adverse event was not actionable where the specific adverse event was identified as a common side-effect. The court similarly rejected plaintiffs allegation regarding the failure to provide data demonstrating the adverse event risks of its drug compared to the risks of other TRT treatments on the market, emphasizing that there was no duty to disclose such information unless Antares had disclosed some other comparative safety data that would render this omission misleading.

Puffery

The two dismissals also reiterate that puffery or vague statements of corporate optimism are not actionable under Section 10(b) and Rule 10b-5 because they are so general that a reasonable investor would not rely on them.

For example, the Antares court deemed statements that the drug was found to be safe, showed positive . . . safe data and that nothing unusual occurred regarding the FDAs review of the drug as vague and general statements of optimism. The court explained statements cannot be read in a vacuum, concluding a reasonable investor would understand Antaress statements on the drugs safety in light of the disclosure of adverse events. The Nabriva court similarly held company press release statements describing Contepos NDA submission as another major milestone, and Contepo as a first in class antibiotic, as classic examples of puffery because both are vaguely optimistic descriptions that make no particularly definite assertions of existing fact and thus provide little basis to mislead a reasonable investor.

Forward-Looking Statements

The dismissals also emphasized the protections afforded forward-looking statements under the safe harbor provision of the Private Securities Litigation Reform Act (PSLRA).

The Nabriva court rejected challenges to statements made by the company in its March 12, 2019 10-K regarding the risk of delay in FDA approval. Plaintiff argued that the characterization of the delay as a risk rather than a certainty was misleading in light of the concerns raised in the FDAs December 2018 Form 483 and that as a result the statement was not a forward-looking statement but rather a misstatement of existing fact. The court rejected the contention that the risks identified had already materialized, reasoning that the expected approval date was still over four months away and that the Form 483 reflected interim feedback and not a final decision.

Opinions

In dismissing the complaints, the courts reiterated that interpretations of clinical data are opinions and emphasized the heightened pleading requirements with respect to opinion statements following the Supreme Courts decision in Omnicare.[4]

In Antares, the court rejected plaintiffs argument regarding the falsity of the companys opinion about the physiologically normal benefits of the drug, concluding that plaintiff had failed to allege that the opinion was either objectively or subjectively false. The court explained that incidents of hypertension, depression or suicide did not render false the companys opinion regarding the drugs ability to provide patients with physiologically normal and steady levels of testosterone.

The court also held a statement regarding the positive safety data resulting from the study was an interpretation of the clinical trial data and as such an opinion. It reasoned the statement was not actionable absent facts showing Antares did not honestly believe the studies produced positive safety data and lacked a reasonable basis. [5] Similarly, the court held plaintiff failed to allege Antares lacked a reasonable basis for its opinion that the drug was safe, and noted a failure to allege that Antares was aware of this comparative risk data when [it] made the statement.

Conclusion

Antares and Nabriva are helpful precedents for pharmaceutical companies defending against securities class action lawsuits based on optimistic statements made about products undergoing FDA approval. The decisions emphasize that alleged misstatements cannot be read in a vacuum, and indicate that plaintiffs cannot simply rely on less-than-stellar feedback from the FDA, coupled with statements of corporate optimism made during the drug approval process.

Excerpt from:
District Courts In New Jersey And New York Dismiss Securities Class Actions Against Life Science Companies Emphasizing the High Pleading Bar With...

Testosterone Replacement Therapy Market Size by Top Key Players, Growth Opportunities, Incremental Revenue , Outlook and Forecasts to 2026 – Latest…

Acerus Pharmaceuticals

Global Testosterone Replacement Therapy Market: Competitive Landscape

This section of the report lists various major manufacturers in the market. The competitive analysis helps the reader understand the strategies and collaborations that players focus on in order to survive in the market. The reader can identify the players fingerprints by knowing the companys total sales, the companys total price, and its production by company over the 2020-2026 forecast period.

Global Testosterone Replacement Therapy Market: Regional Analysis

The report provides a thorough assessment of the growth and other aspects of the Testosterone Replacement Therapy market in key regions, including the United States, Canada, Italy, Russia, China, Japan, Germany, and the United Kingdom United Kingdom, South Korea, France, Taiwan, Southeast Asia, Mexico, India and Brazil, etc. The main regions covered by the report are North America, Europe, the Asia-Pacific region and Latin America.

The Testosterone Replacement Therapy market report was prepared after various factors determining regional growth, such as the economic, environmental, technological, social and political status of the region concerned, were observed and examined. The analysts examined sales, production, and manufacturer data for each region. This section analyzes sales and volume by region for the forecast period from 2020 to 2026. These analyzes help the reader understand the potential value of investments in a particular country / region.

We Offer up to 30% Discount @ https://www.marketresearchintellect.com/ask-for-discount/?rid=208345&utm_source=LHN&utm_medium=888

Key Benefits for Stakeholders:

The report provides an in-depth analysis of the size of the Testosterone Replacement Therapy world market, as well as recent trends and future estimates, in order to clarify the upcoming investment pockets.

The report provides data on key growth drivers, constraints and opportunities, as well as their impact assessment on the size of the Testosterone Replacement Therapy market.

Porters 5 Strength Rating shows how effective buyers and suppliers are in the industry.

The quantitative analysis of the Testosterone Replacement Therapy world industry from 2020 to 2026 is provided to determine the potential of the Testosterone Replacement Therapy market.

This Testosterone Replacement Therapy Market Report Answers To Your Following Questions:

Who are the main global players in this Testosterone Replacement Therapy market? What is the profile of your company, its product information, its contact details?

What was the status of the global market? What was the capacity, the production value, the cost and the profit of the market?

What are the forecasts of the global industry taking into account the capacity, the production and the value of production? How high is the cost and profit estimate? What will be the market share, supply, and consumption? What about imports and export?

What is market chain analysis by upstream raw materials and downstream industry?

Get Complete Report @ https://www.marketresearchintellect.com/need-customization/?rid=208345&utm_source=LHN&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Testosterone Replacement Therapy Market Size, Testosterone Replacement Therapy Market Trends, Testosterone Replacement Therapy Market Growth, Testosterone Replacement Therapy Market Forecast, Testosterone Replacement Therapy Market Analysis

Read the original post:
Testosterone Replacement Therapy Market Size by Top Key Players, Growth Opportunities, Incremental Revenue , Outlook and Forecasts to 2026 - Latest...

Testosterone Replacement Therapy Market Size, Share 2020 Overview, Growth, Demand and Forecast Research Re … – Absolute News Journal

Testosterone Replacement TherapyMarket2020analysis reports provides a significant wellspring of fast information for business strategists and based examination. It provides the Testosterone Replacement Therapybusiness inspection with advancement analysis and the peak value, the income, petition and supply info. Real makers Evaluation of Testosterone Replacement TherapyMarket.

Request a sample copy of the report https://www.marketreportsworld.com/enquiry/request-sample/10881904

Short Detailsof Testosterone Replacement TherapyMarket Report Testosterone replacement therapy (TRT) is a class of hormone replacement therapy in which androgens, often testosterone, are replaced. Testosterone replacement therapy (TRT) is an FDA-approved medical treatment for men of any age who have low testosterone, a hormone necessary for male sexual development.,

Global Testosterone Replacement Therapymarket competition by top manufacturers

Enquire before purchasing this report https://www.marketreportsworld.com/enquiry/pre-order-enquiry/10881904

By the product type, the market is primarily split into

By the end users/application, this report covers the following segments

This report focuses on the Testosterone Replacement Therapy in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.,

Purchase this report (Price4880 USD for single user license) https://www.marketreportsworld.com/purchase/10881904

Table of Contents

1 Market Overview

1.1 Testosterone Replacement TherapyIntroduction

1.2 Market Analysis by Type

1.3 Market Analysis by Applications

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2014-2024)

1.4.1.2 Canada Market States and Outlook (2014-2024)

1.4.1.3 Mexico Market States and Outlook (2014-2024)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2014-2024)

1.4.2.2 France Market States and Outlook (2014-2024)

1.4.2.3 UK Market States and Outlook (2014-2024)

1.4.2.4 Russia Market States and Outlook (2014-2024)

1.4.2.5 Italy Market States and Outlook (2014-2024)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2014-2024)

1.4.3.2 Japan Market States and Outlook (2014-2024)

1.4.3.3 Korea Market States and Outlook (2014-2024)

1.4.3.4 India Market States and Outlook (2014-2024)

1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2014-2024)

1.4.4.2 Egypt Market States and Outlook (2014-2024)

1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)

1.4.4.4 South Africa Market States and Outlook (2014-2024)

1.4.4.5 Turkey Market States and Outlook (2014-2024)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

3 Global Testosterone Replacement TherapySales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

3.1 Global Testosterone Replacement TherapySales and Market Share by Manufacturer (2017-2018)

3.2 Global Testosterone Replacement TherapyRevenue and Market Share by Manufacturer (2017-2018)

3.3 Market Concentration Rate

3.3.1 Top 3 Testosterone Replacement TherapyManufacturer Market Share in 2018

3.3.2 Top 6 Testosterone Replacement TherapyManufacturer Market Share in 2018

3.4 Market Competition Trend

4 Global Testosterone Replacement TherapyMarket Analysis by Regions

4.1 Global Testosterone Replacement TherapySales, Revenue and Market Share by Regions

4.1.1 Global Testosterone Replacement TherapySales and Market Share by Regions (2014-2019)

4.1.2 Global Testosterone Replacement TherapyRevenue and Market Share by Regions (2014-2019)

4.2 North America Testosterone Replacement TherapySales and Growth Rate (2014-2019)

4.3 Europe Testosterone Replacement TherapySales and Growth Rate (2014-2019)

4.4 Asia-Pacific Testosterone Replacement TherapySales and Growth Rate (2014-2019)

4.5 South America Testosterone Replacement TherapySales and Growth Rate (2014-2019)

4.6 Middle East and Africa Testosterone Replacement TherapySales and Growth Rate (2014-2019)

5 North America Testosterone Replacement Therapyby Country

5.1 North America Testosterone Replacement TherapySales, Revenue and Market Share by Country

5.1.1 North America Testosterone Replacement TherapySales and Market Share by Country (2014-2019)

5.1.2 North America Testosterone Replacement TherapyRevenue and Market Share by Country (2014-2019)

5.2 United States Testosterone Replacement TherapySales and Growth Rate (2014-2019)

5.3 Canada Testosterone Replacement TherapySales and Growth Rate (2014-2019)

5.4 Mexico Testosterone Replacement TherapySales and Growth Rate (2014-2019)

8 South America Testosterone Replacement Therapyby Country

8.1 South America Testosterone Replacement TherapySales, Revenue and Market Share by Country

8.1.1 South America Testosterone Replacement TherapySales and Market Share by Country (2014-2019)

8.1.2 South America Testosterone Replacement TherapyRevenue and Market Share by Country (2014-2019)

8.2 Brazil Testosterone Replacement TherapySales and Growth Rate (2014-2019)

8.3 Argentina Testosterone Replacement TherapySales and Growth Rate (2014-2019)

8.4 Colombia Testosterone Replacement TherapySales and Growth Rate (2014-2019)

9 Middle East and Africa Testosterone Replacement Therapyby Countries

9.1 Middle East and Africa Testosterone Replacement TherapySales, Revenue and Market Share by Country

9.1.1 Middle East and Africa Testosterone Replacement TherapySales and Market Share by Country (2014-2019)

9.1.2 Middle East and Africa Testosterone Replacement TherapyRevenue and Market Share by Country (2014-2019)

9.2 Saudi Arabia Testosterone Replacement TherapySales and Growth Rate (2014-2019)

9.3 Turkey Testosterone Replacement TherapySales and Growth Rate (2014-2019)

9.4 Egypt Testosterone Replacement TherapySales and Growth Rate (2014-2019)

9.5 Nigeria Testosterone Replacement TherapySales and Growth Rate (2014-2019)

9.6 South Africa Testosterone Replacement TherapySales and Growth Rate (2014-2019)

11 Global Testosterone Replacement TherapyMarket Segment by Application

11.1 Global Testosterone Replacement TherapySales Market Share by Application (2014-2019)

11.2 Home Using Sales Growth (2014-2019)

11.3 Hospital Using Sales Growth (2014-2019)

11.4 Other Sales Growth (2014-2019)

12 Testosterone Replacement TherapyMarket Forecast (2019-2024)

12.1 Global Testosterone Replacement TherapySales, Revenue and Growth Rate (2019-2024)

12.2 Testosterone Replacement TherapyMarket Forecast by Regions (2019-2024)

12.2.1 North America Testosterone Replacement TherapyMarket Forecast (2019-2024)

12.2.2 Europe Testosterone Replacement TherapyMarket Forecast (2019-2024)

12.2.3 Asia-Pacific Testosterone Replacement TherapyMarket Forecast (2019-2024)

12.2.4 South America Testosterone Replacement TherapyMarket Forecast (2019-2024)

12.2.5 Middle East and Africa Testosterone Replacement TherapyMarket Forecast (2019-2024)

12.3 Testosterone Replacement TherapyMarket Forecast by Type (2019-2024)

12.3.1 Global Testosterone Replacement TherapySales Forecast by Type (2019-2024)

More here:
Testosterone Replacement Therapy Market Size, Share 2020 Overview, Growth, Demand and Forecast Research Re ... - Absolute News Journal

Male Hypogonadism Market Increasing Demand with Leading Key Players, Revenue Growth Analysis and Industry Share Price, Forecast 2025 – amitnetserver

Global Male Hypogonadism Market: Snapshot

Hypogonadism in males refers to a condition in the male body where the testes show a significantly reduced level of functioning than normal. The overall result of male hypogonadism is a reduction in the rate of biosynthesis of male sex hormones. This state is more commonly known as interrupted stage 1 puberty. Hypoandrogenism, or the low androgen or testosterone level in a male can vary in severity from person to person. It is often the cause of partial or complete infertility. There are multiple forms of male hypogonadism and even more ways to classify them. Most endocrinologists commonly classify male hypogonadism on the basis of the level of defectiveness of the male reproductive system.

In many cases, doctors also measure the level of gonadotropins to classify a patient between primary and secondary male hypogonadism. Primary male hypogonadism refers to the cause of the condition being due to defective gonads. There are different types of primary male hypogonadism, including Turner syndrome and Klinefelter syndrome. Secondary male hypogonadism is caused by defects in pituitary or hypothalamic glands. They include Kallmann syndrome and hypopituitarism.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1127

Global Male Hypogonadism Market: Overview

Male Hypogonadism refers to a clinical condition, wherein the testes fail to produce enough testosterone leading to delayed puberty or incomplete development. The condition is related to impaired development of muscle mass, development of breast tissues, impaired body hair growth, and lack of deepening of the voice.

The male Hypogonadism market can be segmented by therapy, type, drug delivery, and geography.

The report presents an in-depth analysis of the global male hypogonadism market with current trends and future estimates to explain the imminent investment pockets. The quantitative analysis of the market for the forecast period from 2017 to 2025 will enable stakeholders to capitalize on the prevailing growth opportunities.

Global Male Hypogonadism Market: Trends and Opportunities

The top driver of the male hypogonadism market includes rising prevalence of testosterone deficiency among men, increasing infertility rates, and increasing awareness among individuals about hypogonadism treatment due to awareness drives organized by several governments across the world. Moreover, high risk of hypogonadism among the geriatric population with obesity and diabetes, and increasing prevalence of chronic disorders among the geriatrics are further expected to boost the markets growth.

However, factors such as high side effects of testosterone products are challenging the growth of testosterone replacement therapy market. Top players in the market are focused on research and development to introduce newer products with fewer or negligible side effects and improved results. For example, LPCN 1111, a product which is under development from Lipocine Inc., is a newer testosterone prodrug that utilizes Lipral technology for enhanced systemic absorption and for enhanced solubility of testosterone. Nevertheless, technological advancements are anticipated to extend new opportunities to the markets growth.

Global Male Hypogonadism Market: Regional Overview

The global male Hypogonadism market can be analyzed with respect to the regional segments of North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. North America held the majority share of the global market in the recent past and is expected to retain its dominant position in the near future. This is mainly due to the rise in the number of individuals suffering from primary and secondary conditions of hypogonadism, and rising awareness among individuals about treatment options for the condition. Moreover, the presence of ultra-modern healthcare infrastructure and increasing popularity of technologically advanced products are expected to offer new opportunities for top players in this market. The region is closely followed by Europe.

Asia Pacific is expected to offer lucrative opportunities to this market due to the modernization of the healthcare infrastructure in the emerging economies of India and China and the increasing awareness about the treatment for the condition. In Asia Pacific, the increasing prevalence of hypogonadism and infertility rates along with the rising geriatric population base with diabetes and obesity are propelling the growth of this market. China, Taiwan, and Malaysia are some of the countries that display the highest rate of male hypogonadism.

Major Companies Mentioned in Report

Some of the key players in the male Hypogonadism market include AbbVie Inc., Astrazeneca plc, Eli Lilly and Company Ltd., Merck & Co. Inc., SA, Finox Biotech, Laboratories Genevrier, Teva Pharmaceutical Industries Ltd., Allergan plc, Bayer AG, Endo International plc, IBSA Institut Biochimque, and Ferring.

Key players are focused on product approval for growth considerations and to cater to the changing demand of the industry. The introduction of innovative and technologically advanced products is also the focus of key players to increase their market share and for serving patients in a better manner.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/male-hypogonadism-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,3739 Balboa St # 1097,San Francisco, CA 94121United StatesTel: +1-415-520-1050

Continue reading here:
Male Hypogonadism Market Increasing Demand with Leading Key Players, Revenue Growth Analysis and Industry Share Price, Forecast 2025 - amitnetserver

Peek on Low T Therapy Market Future, Extensive Studies and Prediction of Top Manufacturers Condition: AbbVie, Endo International, Eli Lilly – 3rd…

The Low T Therapy Market (2020) research report explores the market in terms of Revenu, Emerging Market Trends and Driver includes up to date analysis and forecasts for various market segments, major players, and all geographical regions till 2027.

The coronavirus epidemic (COVID-19) has affected all aspects of life around the world. This has changed some of the market situation. The main purpose of the research report is to provide users with a broad view of the market. Initial and future assessments of rapidly changing market scenarios and their impact are covered in the report. The report will account for Covid19 as a key market contributor.

The top players covered in Low T Therapy Market are: AbbVie, Endo International, Eli Lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals

Download Sample PDF PagesClick Here!

This report sample includes: Brief Introduction to the research report, Table of Contents (Scope covered as a part of the study), Top players in the market, Research framework (presentation), Research methodology adopted by Worldwide Market Reports

Low T Therapy Market Outlook:

Global Low T Therapy market report provides exclusive coverage that has been provided for market drivers and challenges & opportunities for a country-level market in the respective regional segments. The report comprises a competitive analysis of the key players functioning in the market and covers in-depth data related to the competitive landscape of the market and the recent strategies & products that will assist or affect the market in the coming years.

Market Drivers and the Risks Associated with the Low T Therapy Market:

The international Low T Therapy market has been characterized by several primary factors, with each factor tends of playing a crucial role in the boom of the market. The growth in the products has doubled with the smoother availability of the customer base that has been helping the company of flourishing globally. On the other hand, the presence of a dynamic supply chain has helped the company to grow exponentially. Therefore, regarding the increase in the opportunities of the market Low T Therapy faces severe complaints from all the aspects.

Enumerating some of the fundamental parameters encompassed in the report:

Major Geographical Regions and Market of the Low T Therapy Market:

When a better look taken at the areas, the market has concentrated, and the file interior the important makes a strong point of Europe, Middle East & Africa, Asia Pacific, Latin America, and North America. These areas have studied regarding the hooked-up traits and the diverse possibilities in addition to the outlook that allows inside the benefitting of the market ultimately.

Buy This Complete Business Report: Access Insightful Study With Over 100+ Pages, List of Tables and Figures, Profiling 10+ Companies Click Here!

Low T Therapy Market Report Covers Following Questions:

Customization Service of the Report: Place Query: Click Here!

Worldwide Market Reports provides customization of reports as per your request. This report can be personalized to meet your requirements. Get in touch with our research team, who will make sure you get a report that suits your necessities.

See original here:
Peek on Low T Therapy Market Future, Extensive Studies and Prediction of Top Manufacturers Condition: AbbVie, Endo International, Eli Lilly - 3rd...

Key End-use Industries to Surge Sales of Pearl Extract During the Forecast Period Cole Reports – Cole of Duty

Introduction:

Skincare market has witnessed immense growth over the past years with its popularity growing day by day. For years manufacturers of skin care products are focusing on introducing skin care products with natural and organic ingredients. This includes natural ingredients such as fruits and plants extract or even mud. Apart from this, there has also been growing demand for products such as pearl extracts which consist of essential amino acids that help skin to look youthful. The nacre of the pearl helps stimulate the metabolic activities of the genetic material in the cell thus accelerating the cell regeneration process. All types of mollusks can produce peal extract, however, two groups of pearls known as bivalves or clams can produce nacreous pearls which are highly significant forms of pearls produced. Pearl extracts are an excellent alternative for various types of synthetic skin care products and are widely used for acne treatment. The global pearl extract market is expected to witness significant growth in the near future due to its extensive benefits in the skincare space.

To Get Free Sample Request Visit @https://www.persistencemarketresearch.com/samples/20506

Pearl Extract Market Segmentation

Global pearl extract market is segmented on the basis of source, end use, and sales channel. On the basis of source, the global pearl extract market is segmented into, freshwater pearls and saltwater pearls. Pearl extract obtained from freshwater is of great significance and hence would contribute a significant market share in the global pearl extract market. A wide variety of pearl extracts have been introduced in the recent past years to help deal with skin care problems thus accelerating the market growth of the pearl extracts market. On the basis of end use the global pearl extract market is segmented into, cosmetic industry, medical industry and other industries. Cosmetic industry segment can be further sub-segmented into, skin moisturizers, skin whitener, skin repair, and others. In medicine, pearl extract is widely used as anti-inflammatory and detoxification agent. The global pearl extract market is expected to witness significant revenue generation over the forecast period. On the basis of sales channel, the global pearl extract market is segmented into, direct and indirect sales channels.

On the basis of the region, the global pearl extract market is segmented into, North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. Europe is estimated to account for the largest market share in the global pearl extract market as growing number of manufacturers of skin care products are realizing the benefits of pearl extract and hence are incorporating it into their products thus, contributing towards the market growth. Asia Pacific and North America market are expected to account for a considerable market share in the global pearl extract market. Pearl extracts are aragonite (CaCO3) and traces of conchiolin, a silk-fibroin like compound which make it extremely beneficial in the skin and medical treatment. For example, pearl extract can be helpful for individuals with low calcium content and improve the condition called osteoporosis. Japan is one of the largest pearl producers in Asia Pacific market with Australia, Philippines, Myanmar, and Malaysia being the other major producers.

Pearl Extract Market Global Market Trends and Market Drivers:

Pearl extract is widely used as an extremely important ingredient in a number of skin care applications and constitutes a range of anti-aging and anti-acne benefits. The pearl extract powder is either available in the form of oral tablets or as an ingredient in a number of applications. Increasing awareness with respect to the essential benefits of pearl extracts in skin care industry is expected to result in its accelerated market revenues over the forecast period. Pearl extracts provide anti-inflammatory, moisturizing, skin-replenishing, anti-infective properties resulting in youthful skin and glow. Pearl extract works by promoting skin regeneration thus slowing the ageing process and delivering younger natural skin. Increasing demand for natural skin care products is expected to contribute towards increasing market revenues for pearl extract market. However, lack of supply and high prices of pearl extracts is expected to hamper the overall market growth over the forecast period.

For More Details and Order Copy of this Report Visit @https://www.persistencemarketresearch.com/checkout/20506

Pearl Extract Market Key Players:

Variety of pearl extract have been introduced by the manufacturers and some of the global market players manufacturing pearl extract market include, Beiersdorf, Pacifque Sud Ingrdients, Croda Inc., Longevity Power Inc., Southern Cross Botanicals, Essential Oils of Tasmania and others.

Go here to read the rest:
Key End-use Industries to Surge Sales of Pearl Extract During the Forecast Period Cole Reports - Cole of Duty

Antioxidant Foods That Improve Your Health – Newsmax

Antioxidants are compounds critical to the production of energy and themaintenance of health and youth. Dr. Jacob Teitelbaum, author of the book From Fatigued to Fantastic! says that although oxygen is necessary for survival, too much of it is toxic.

Using oxygen to create energy in our bodies results in the production of toxic free radicals which set up ongoing, self-sustaining chain reactions of molecular damage, he explains. Doctors who specialize in anti-aging medicine use antioxidants as well as other key tools like bioidentical hormones to keep their patients healthier longer by preventing free radical damage.

The best way to obtain antioxidants is through food, says noted sports medicine physician Dr. Gabe Mirkin. "Eating fruits, vegetables, nuts, and legumes will help you get the intake of antioxidants you need."

New Aging Research Reveals Key to Long, Healthy Life

Here are 10 foods chock full of the good stuff:

1. Dark Chocolate. Teitelbaum says that eating dark chocolate is a fun way to get antioxidants. According to the results of a study conducted at Cornell University, the concentration of cancer-fighting antioxidants in hot cocoa was significantly higher than in red wine, green tea, or black tea.

2. Artichokes. This tasty veggie has a long history of healing properties and is a great source of dietary fiber, minerals, and antioxidants. They are especially rich in the antioxidant known as chlorogenic acid, which may reduce the risk of certain cancers, type 2 diabetes, and heart disease.

3. Beets. These veggies are a great source of fiber, potassium, iron, folate, and antioxidants. Several test-tube studies have shown that beets lower the risk of certain cancers in the colon and digestive tract thanks to a group of antioxidant compounds called betalains. Betalains have also been linked to reducing inflammation and relieving arthritis pain.

Over 50? Serious Brain Nutrition Combats Scary Mental Decline

4. Pecans. Nuts are a good source of healthy fats and minerals, and also contain a high amount of antioxidants, says Mirkin. One study found that people who consumed 20 percent of their total calories from pecans experienced significantly increased blood antioxidant levels.

5. Spinach. This nutritionally dense but very low calorie vegetable is loaded with vitamins, minerals, and antioxidants. Its a great source of lutein and zeaxanthin, two antioxidants that help protect your eyes from UV damage.

6. Tomatoes. The health benefits of tomatoes include eye care, good stomach health, and reduced blood pressure. This popular fruit, often mistaken for a veggie, also includes a number of antioxidants that have been proven to fight different forms of cancer, according to the Harvard T.H. Chan School of Public Health. Tomatoes contain lycopene, an antioxidant that is highly effective in fighting cancer-causing free radicals. Remarkably, the health benefits even can be obtained from processed tomato products like ketchup.

Heart Surgeon's Secret to Healthy Blood Pressure

7. Beans. These legumes are inexpensive and healthy while being incredibly rich in fiber, says Mirkin. They are also one of the best plant sources of antioxidants. One of these is called kaempferol, which has been linked to anti-cancer benefits.

8. Kale. This hearty green vegetable is one of the most nutritious in the plant world, says Mirkin. Its rich in vitamins A, K, and C as well as antioxidants. The red-leafed variety of kale contains higher levels of these antioxidants, which is why nutrition experts advise us to eat a rainbow diet foods rich in a variety of colors.

9. Strawberries. These are among the most popular berries on the planet. They also contain anthocyanins, which help reduce the risk of heart disease. The brighter the red, the higher the amount of anthocyanins.

10. Blueberries. While eating large amounts of sugary fruit is not recommended for those with diabetes, blueberries are low in calories and sugar but packed with antioxidants. Animal studies have shown that blueberries may stave off cognitive decline. In addition, the anthocyanins in blueberries have been shown to reduce the risk of heart disease by lowering LDL cholesterol levels and blood pressure.

2020 Newsmax. All rights reserved.

Link:
Antioxidant Foods That Improve Your Health - Newsmax

Cation-induced shape programming and morphing in protein-based hydrogels – Science Advances

Abstract

Smart materials that are capable of memorizing a temporary shape, and morph in response to a stimulus, have the potential to revolutionize medicine and robotics. Here, we introduce an innovative method to program protein hydrogels and to induce shape changes in aqueous solutions at room temperature. We demonstrate our approach using hydrogels made from serum albumin, the most abundant protein in the blood plasma, which are synthesized in a cylindrical or flower shape. These gels are then programmed into a spring or a ring shape, respectively. The programming is performed through a marked change in stiffness (of up to 17-fold), induced by adsorption of Zn2+ or Cu2+ cations. We show that these programmed biomaterials can then morph back into their original shape, as the cations diffuse outside the hydrogel material. The approach demonstrated here represents an innovative strategy to program protein-based hydrogels to behave as actuators.

Dynamic biomaterials that undergo conformational changes can enable artificial tissue structures, which could experience morphological transformations, and soft robotics, which could react and change in response to their environment. Currently, most common shape-morphing materials are based on polymers and require switching between a stiff and a soft phase (1). These materials typically rely on two or more network skeletons, sharing the same three-dimensional (3D) space (2), or have a chemical response to small ions (3, 4). Programming, defined as the capability of fixing a temporary shape in a material, requires a marked increase in stiffness, in a reversible manner (5). The initial shape recovery entails a switch from a stiff to a soft phase and is typically realized by compromising the integrity of the secondary network, by changing the temperature (1, 6), pH (7), or solvent (8, 9), or through photoswitching (10, 11).

Protein-based hydrogels use a protein as their primary network, in a water-rich environment (12). These hydrogels retain many of the characteristics displayed by the polymer-based materials but can harvest from a much more diverse biofunctional library. Proteins accomplish many life-supporting functions, from structural role to enzymatic reactivity, and their function is, in most cases, directly related to their folded 3D structure. While there is a substantial diversity for the starting material, when compared to polymers, proteins are stable and functional in a much narrower range of temperatures, pH, or salt conditions and require a water-based environment. Since the mechanical response of a material depends directly on the concentration of its constituent network nodes (1315), the range of obtainable stiffness for protein-based hydrogels is extremely limited: the protein needs to be above the critical gelation concentration to be turned into a biomaterial and below its specific solubility limit (1517). This narrow range allows for a change in a stiffness of only ~10 to 30%, depending on the starting protein. Furthermore, well-defined cross-linked network connections are critical to ensure a high shape recovery ratio (18). Unlike most linear polymer molecules, which can entangle like spaghetti in a bowl, globular proteins have well-defined 3D structures, acting as hard spheres. This structural integrity provides an excellent control over the cross-linking points and density, while preserving the tertiary structure of the network nodes.

Recently, we have introduced a new method to obtain shape memory in protein-based hydrogels by stiffening them through adsorbed polyelectrolytes (19). Our approach relies on producing protein hydrogels from bovine serum albumin (BSA), which is homologous to human serum albumin, the most abundant protein in blood plasma. BSA solutions can be turned into completely covalently cross-linked hydrogel biomaterials when starting from solutions with protein concentrations above 1 mM (17, 20). Below 1 mM, BSA hydrogels show irreversible plastic deformation under force, indicative of incomplete cross-linking (17). Because of the overall charge of BSA, these protein hydrogels have been programmed by stiffening, induced by the secondary network made from positively charged polyelectrolytes (19). The shape change was induced in this case via the unfolding response of the protein domains in chemical denaturants with complete recovery upon removal of the denaturing solution. In the unfolding phase transition responsible for shape memory, the proteins lose their tertiary structure and show a remarkable decrease in stiffness. This transition is highly repeatable, as protein folding has been tightly controlled by billions of years of evolution. However, the polyelectrolytes adsorption is irreversible, and because of their large size, the loading capacity is relatively limited, resulting in a change in stiffness of up to ~6.5-fold. Here, we explore the viability of using divalent cations to stiffen protein-based hydrogels toward programming them in various shapes. We then manage to morph back the protein materials from the temporary programmed shape to the initial permanent shape through simple diffusion. It has been previously shown, for other protein hydrogels (21) and peptide-based hydrogels (22), that divalent cations can reinforce their network. It is also well known that BSA can bind cations at various exposed amino acids (23, 24). For example, divalent cations such as Ni2+, Cu2+, and Zn2+ were shown to bind histidine (25, 26) and tryptophan (24), and to bridge cysteine amino acids (27). Adsorption of cations was also associated with an increase in the mechanical stability of proteins at the molecular level (28, 29). Here, we explore this mechanical change to induce the increase in stiffness needed to program protein-based biomaterials in various shapes (Fig. 1). The small ions have the advantage of allowing much higher loading of positive charge, leading to a 17-fold stiffening, and the capacity to diffuse outside the programmed material. This novel implementation of programming protein-based hydrogels with small ions is an important step toward obtaining biocompatible materials that can adjust their shape.

(Left) BSA-based protein hydrogels are fabricated using a light-activated reaction, in the presence of ammonium persulfate (APS) and tris(bipyridine) ruthenium(II) chloride [Ru(bpy)3]2+. (Right) Following synthesis, the protein hydrogels are exposed to Zn2+ or Cu2+, which reversibly increases their stiffness by up to 17-fold. This stiffening effect can be used for shape programming.

Protein-based hydrogels can be obtained using various cross-linking strategies, such as treatment with glutaraldehyde (20) and enzymatic reactions (30), using protein-based lock-and-key ends (31, 32) or photoactivation (12). Here, we use photoactivation via tris(bipyridine) ruthenium(II) chloride ([Ru(bpy)3]2+) to obtain protein-based hydrogels made from BSA (Fig. 1). This reaction was shown to produce covalent carboncarbon bonds at the exposed tyrosine amino acid sites between adjacent protein domains (12). The advantage of using light to trigger the start of the cross-linking reaction is that it allows us to load the reaction mixture in the desirable shape, without any change in viscosity before light exposure.

Our first step was to explore the range of concentrations of two positively charged ions, which can potentially increase the stiffness of protein hydrogels and allow for shape programming. The change in stiffness of protein-based hydrogels in the presence of positively charged ions was quantified using our force-clamp rheometry apparatus (17, 33). We first produced cylindrical-shaped hydrogels starting from 2 mM BSA, using polytetrafluoroethylene (PTFE) tubes with an inner diameter of 0.56 mm. We chose 2 mM as starting concentration, as our polymerization method produces complete cross-linking for BSA and the hydrogels show reversible behavior without any plastic deformations in the sampled force range (17). Using surgical thread, these gels were then attached in our force-clamp rheometer via two metal hooks connected to a voice-coil motor and force sensor, respectively (Fig. 2, inset, and see also Materials and Methods). Following incubation for 30 min in a phosphate buffer saline with the desired cation concentration, the mechanical response of treated BSA hydrogel was measured in the 0- to 4-kPa range (Fig. 2). The change in stress as a function of strain, as the applied force is increased linearly with time, can be used to assess the stiffness of the material, as the slope in the rising part of the trace directly reports on the dynamic Youngs modulus. Typically, hydrogels made from globular proteins such as BSA also show hysteresis in the stress-stain curves (Fig. 2A). This hysteresis disappears for BSA hydrogels when exposed to chemical denaturants, which break down the tertiary structure of the protein domains forming the hydrogel network (12, 17). This hysteresis was related to the imbalance between the forces where unfolding and refolding take place, with the unfolding transition occurring at much higher forces than the refolding (34), and can allow for large energy dissipation before failure (35, 36). BSA hydrogels show an up to 5-fold increase in stiffness when treated with Cu2+ (50 kPa in 1.5 M Cu2+ from 11 kPa) and a 17-fold increase in stiffness in the presence of Zn2+ (191 kPa in 2 M Zn2+) (Fig. 2B). The stiffening of BSA hydrogels in 2 M Zn2+ is several orders of magnitude greater than that reported for the same gels when treated with polyelectrolytes (19) and should allow for more complex programmed shapes. The stiffening effect seems to depend more on the solution concentration of cations rather than their nature (Fig. 2B). The main advantage of Zn2+ over Cu2+ is its higher solubility in water, which allows us to prepare solutions with higher concentrations and observe greater stiffening.

(A) Chemomechanical changes induced by adsorption of various concentrations of Zn2+ (left) and Cu2+ (right) by protein hydrogels made from 2 mM BSA. The mesh highlights the force-loading part, used to assess the change in stiffness, and the thick, black curve follows the final strain at 4-kPa stress. Inset: Schematics of a hydrogel tube pulled under a feedback-controlled force, where the set point (SP) was increased and decreased linearly with 40 Pa/s. (B) Change in measured Youngs modulus as a function of cation concentrations. Both Zn2+ and Cu2+ induce stiffening when adsorbing to BSA-based hydrogels. Lines between points are eye guides. Error bars are SD (n = 3).

Apart from the stiffening effect, incubation of protein hydrogels in solutions with high concentrations of cations improves their mechanical failure properties (22). For these tests, we use a typical bone shape, where the BSA hydrogels were extended until failure or maximum force range of our force sensor (Fig. 3A). BSA-based hydrogels show an increase in both toughness and failure stress with increasing cation concentration. The measured toughness, which represents the ability of a material to absorb energy and deform without fracturing and is derived from the area under the pulling stress-strain curve (Fig. 3B and 3C, left), increased from 1 to 2.8 kJ/mol with cation concentration. The failure stress increased from 15 to 33 kPa. The maximum elongation did not show a substantial variation with cation concentration. This behavior suggests that, while the stiffness is probably given by the increase in the mechanical stability of protein domains (27) and noncovalent bridging (22) at ~120%, the primary network of the BSA hydrogels is the one starting to fail, experiencing irreversible breaking of covalent bonds. Hence, the cross-linking geometry is the limiting factor for extensions, and for further improvements in maximum elongation, the primary hydrogel network would require refinement.

(A) Picture of a gel casted using a bone-shaped silicone mold (left and middle) and attached in the force-clamp rheometer (right). (B) Stress versus strain of BSA hydrogels immersed in Zn2+ (left) and Cu2+ (right) and pulled until breaking. (C) Toughness (left), failure stress (middle), and maximum elongation (right) of BSA hydrogels incubated with increasing concentrations of Zn2+ (magenta) and Cu2+(blue). Toughness increased from 1.0 0.1 to 2.8 0.7 kJ/mol in the presence of 1.5 M Zn2+ and to 2.9 0.7 kJ/mol in the presence of 1.5 M Cu2+. The breaking stress increases from 15 2 to 33 5 kPa when BSA hydrogels were treated with 1.5 M Zn2+ and to 36 5 kPa when treated with 1.5 M Cu2+. The failing strain shows little variation (106 18% versus 107 15% in 1.5 M Zn2+ and 146 21% in 1.5 M Cu2+). Error bars are SD (n = 3). (Photo credit: Luai R. Khoury, UWM; Marina Slawinski, UWM).

While stiffening through a secondary network is necessary for programing in-shape of the hydrogel material, the dynamics of morphing from the programmed to the initial shape will directly depend on the diffusion of the cations outside the hydrogel. To monitor this effect, we first programmed a cylindrical hydrogel in a U-shape (Fig. 4). BSA hydrogels were mounted in a U-shape configuration, corresponding to a bending angle of 180 (as defined in Fig. 4, inset), and incubated for 30 min in three different concentrations of Zn2+ (8, 37). The fixity, Rf, which reports on the degree of the programmed hydrogel to maintain its shape when taken out of the mold used during the programming phase, varied from 96 3% in 2 M Zn2+ to 58 15% in 1 M Zn2+ (fig. S2). The fixity of protein hydrogels depends on the amount of stiffening that can be induced when dosing with cations. Hence, the ~17-fold increase in stiffness when incubating BSA hydrogels with 2 M Zn2+ produces a programmed bending degree closer to the U-shape mold than the equivalent ~2-fold stiffening in 1 M Zn2+ (Fig. 4 and fig. S2). These values are comparable with those measured for BSA hydrogels programmed with polyethylenimine (19) and with other polymeric materials using double network or polymer-ion interactions (37). As shown in Fig. 4, when a programmed hydrogel is immersed in regular Tris buffer, the bending angle decreases to a final value of ~45 in ~3 min. The mechanism behind obtaining the temporary shape involves a combination of ionic cross-linking (4) and the stabilization due to divalent cations of BSA domains (38). The shape morphing results from the diffusion of these divalent ions in the surrounding medium (Fig. 4).

Measured programmed angle of a U-shape gel, , as a function of time, upon immersion from Zn2+ into regular Tris buffer. Inset: Pictures of the hydrogel recovering from a U-shape at four different time points. Second inset from the left shows how the angle is measured. The error bars represent SD (n = 3). Movie S3 accompanies this figure. (Photo credit: Luai R. Khoury, UWM; Marina Slawinski, UWM).

Using the large change in stiffness of BSA hydrogels, induced by immersion in Zn2+ and Cu2+ solutions, we programmed cylindrically casted biomaterials into a spring shape and flower-casted materials into a ring shape (Fig. 5, top, and fig. S3). As shown with polyelectrolytes, a ~6.5-fold increase in stiffness already suffices to program BSA hydrogels into a spring shape, and both Zn2+ and Cu2+ induce a strong enough stiffening (up to ~17-fold). The main advantage of the small ions over polyelectrolytes is their diffusion, which happens relatively fast (<5 min). Furthermore, in the present case, the shape morphing is driven by simple diffusion and does not require compromising the primary protein network with the help of a chemical denaturant. Another advantage of the increase in Youngs modulus of BSA hydrogels in the presence of cations is that more complex shapes can be obtained. For example, we demonstrate the morphing from a ring to a flower shape (Fig. 5, bottom, and fig. S3). Compared to the spring shape, in this case, there are no free ends that can release any torsional tension. To obtain this complex shape morphing, we first casted the hydrogel in a flower-like shape using a silicone mold. Following the light-activated cross-linking reaction, we then programmed the hydrogel into a ring shape by mounting it onto a plastic tube, which was then immersed in the cation solution for 30 min. When removed from the plastic tube into a Zn2+ solution with the same concentration, the hydrogel maintains the ring shape (Fig. 5B, bottom left). However, when immersed into a regular Tris buffer, the ring shape quickly morphs into the original flower shape (Fig. 5B, bottom left, and movie S1).

(A) BSA hydrogels were casted in cylindrical shape in PTFE tubes (top left) and programmed in a spring shape using a negative cast, by immersion in 2 M Zn2+ solution (top right) or 1.5 M Cu2+ solution (middle right) for 30 min; BSA hydrogels were produced in a flower shape using a silicone mold (bottom left) and programmed into a ring, by immersion in 2 M Zn2+ solution for 30 min (bottom right). (B) Morphing from the programmed shape into the casted shape of BSA hydrogel upon immersion in regular Tris buffer at time 0 (left) and 5 min (right) for the hydrogels from (A). Movies S1 and S2 accompany this figure. (Photo credit: Luai R. Khoury, UWM; Marina Slawinski, UWM).

Polymer-based hydrogels have found various applications for shape memory and shape morphing. While these approaches can be made biocompatible, polymers cannot reach the same diversity and control over the sequence and structure as proteins. The approach demonstrated here enables shape morphing in protein-based hydrogels, which could harvest the best of both worlds. This approach relies on the stiffening induced by Zn2+ and Cu2+ to program a permanent shape into a new temporary configuration, and the diffusion of these ions outside the material enables the recovery of the original shape. While we demonstrate this approach with both Zn2+ and Cu2+, we envision that Zn2+ will enable more biologically relevant applications, as it is substantially less toxic than Cu2+.The main advantages of cation-programmed protein hydrogels are that the attainable stiffness is much higher than in regular buffer (~17-fold), enabling programming in complex shapes, and that the fast diffusion of the small ions leads to fast irreversible morphing (<5 min). Furthermore, the shape change is taking place in an aqueous environment at room temperature, which is compatible with conditions present in the human body. Permanent shape morphing based on protein hydrogels and cations could find applications for various implants (39) and injectable hydrogels (40). In addition, the shape morphing method demonstrated here, from a temporary to a permanent profile, does not require denaturation of the tertiary structure of protein domains inside the hydrogels. Hence, this approach allows the preservation of the functionality of proteins forming the skeleton of the hydrogel. In conclusion, the approach presented here provides a remarkable combination of biological diversity and programming capability.

BSA [molecular weight (MW), ~66.5 kDa) was purchased from Rocky Mountain Biologicals. Sodium phosphate monobasic anhydrous (NaHPO4) (MW, 119.98 g/mol) was obtained from Research Products International. Sodium chloride (NaCl) (MW, 58.44 g/mol) was purchased from Thermo Fisher Scientific. Ammonium persulfate (APS) [(NH4)2S2O8] (MW, 228.20 g/mol; 1 M) solution, tris(bipyridine) ruthenium(II) chloride {[Ru(bpy)3]2+} (MW, 748.62 g/mol; 6.67 mM) solution, Trizma base NH2C(CH2OH)3 (MW, 121.14 g/mol), hydrochloric acid (HCl) (37%), zinc sulfate monohydrate (ZnSO4H2O; purity, 99.9%) (MW, 179.47 g/mol), copper(ii) chloride dihydrate (CuCl22H2O; purity, 99.99%) (MW, 170.48 g/mol), and Sigmacote were purchased from Sigma-Aldrich. Tris [20 mM Tris-NaCl and 150 mM NaCl (pH ~7.4)] and phosphate-buffered saline [10 mM NaHPO4 and 150 mM NaCl (pH ~3)] were used as buffers. Double distilled H2O was used in all solution preparations.

Three different shapes of BSA-based hydrogels were prepared in this study. First, a BSA-based hydrogel mixture was prepared by mixing 2 mM BSA solution with 1 M APS and 1 M [Ru(bpy)3]2+ in a volume ratio of 15:1:1. To prepare the hydrogels with the cylindrical shape, we followed the same procedure as described in our previous studies (17, 33). Briefly, PTFE tubes (inner diameter, 0.56 mm; Cole-Parmer) were passivated with Sigmacote for 5 to 10 min and dried thoroughly. The solution mix was then injected, and the tube was placed under a light source for 30 min. The bone- and flower-like shape hydrogels were prepared starting from a custom-made silicone rubber mold made of Dragon Skin 30 (purchased from Smooth-On) (fig. S1). The bone-shape hydrogel samples had an overall length of 9 mm. The gauge length and width are 5 and 1 mm, respectively, and the thickness is 1 mm (fig. S1A). The flower-like shape sample has a width of 0.8 mm and a thickness of 1 mm (fig. S1B). Thereafter, the molds were passivated with Sigmacote for 10 min. The hydrogel mixture was casted into the slot and covered with a glass coverslip to reduce evaporation. The loaded molds were then placed under a 100-W mercury lamp for 30 min, after which the hydrogel samples were removed from the molds and immersed in Tris solution.

The mechanical investigation of hydrogel samples was carried out using a force-clamp machine, as described in previous studies (17, 33). A force-ramp protocol with a rate of 0.04 kPa/s was applied on the hydrogel sample while immersing in Tris solution at room temperature. Afterward, the hydrogel sample was immersed for 30 min at room temperature into one of two cations solutions: Zn2+ and Cu2+, which were dissolved in phosphate buffer saline at different concentrations. We chose a 30-min incubation time, as for the gels used here (with cylindrical shape and a diameter of 0.56 mm or with a square cross section of 0.5 mm by 0.5 mm), the material fully equilibrates with the solvent environment. Then, same force protocol was applied on the treated hydrogel sample. The Youngs modulus, toughness, and breaking stress and strain were calculated from stress-strain curves.

The shape programming and morphing of the BSA-based hydrogel samples were performed by starting from the tube or the flower shapes. First, a 2 mM BSA-based hydrogel was synthesized inside the plastic tube or the silicone mold. Then, the hydrogels obtained in the tubes were fixed in a 3D spiral-like shape or U-shape, while the flower-shaped hydrogels were fixed in a circular shape around a 5-ml plastic tube. Following treatment with Zn2+ or Cu2+ for 30 min at room temperature, at various concentrations, the gels were removed from the fixing mold and placed into the same solution buffer. The shape morphing was then induced by transferring the fixed gels from the Zn2+ or Cu2+ solution into a regular tris buffer. Recordings were performed with a Panasonic digital camera, in the time-lapse video mode, with a frame saved every 3 s.

All data acquisition and analysis of the mechanical behavior of hydrogels was performed in Igor Pro (WaveMetrics). All image processing for measuring bending angle of the U-shape gels was accomplished in ImageJ. The stress values were calculated by dividing the measured force (millinewtons) to the cross-section area, while the strain values were obtained from the measured extension, in respect to the tethered gel length.

To quantify the ability of our protein hydrogels to memorize their temporary shape and the dynamics of recovery from the temporary programmed shape into the initial permanent shape, we used the U-shape recovery method (37, 41). In this approach, the hydrogel is programmed into a U-shape, and a bending angle is defined as the difference between the original orientation (in our case, 180) and the programmed orientation (the angle between the arms of the programmed shape). The shape fixity, Rf, reports on how well the temporary programmed shape can memorize the geometry of the casting mold in the presence of cations and was calculated asRf=0p100where 0 was the measured bending angle at time zero, right after the gel was removed from the programming process. p is the expected programmed angle (which, for the U-shape, is 180). The dynamics of switching from the temporary programmed shape into the initial permanent shape was also quantified by monitoring (t), the bending angle of the U-shape hydrogel in tris buffer, at various times t.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

Acknowledgments: Funding: This research was funded by the National Science Foundation (grant numbers MCB-1846143 and DBI-1919670), the Greater Milwaukee Foundation (Shaw Award), and the University of Wisconsin system (RGI 101X396). M.S. and D.R.C. also acknowledge support from SURF and UR@UWM. Author contributions: L.R.K. and I.P. designed the research. L.R.K., M.S., and D.R.C. performed the research. L.R.K. and I.P. analyzed the data. I.P. wrote the manuscript with input from all authors. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Read the original post:
Cation-induced shape programming and morphing in protein-based hydrogels - Science Advances

Here’s My Top Stock to Buy in May – The Motley Fool

I bought quite a few stocks in March and April. Am I now going to follow the old investing adage "sell in May and go away"? Absolutely not.

However, there are still a lot of stocks that I like. Several tech stocks, dividend stocks, and financial stocks are on my watchlist. But my top pick doesn't fall into any of these categories. Instead, it's a biotech stock that's already up by a solid double-digit percentage this year and has plenty of room to run. Here are three reasons my top stock to buy in May is...Vertex Pharmaceuticals (NASDAQ:VRTX).

Image source: Getty Images.

Some investors are concerned that the recent stock market resurgence could fizzle. Although I don't pretend to know what will happen next with the market, I do share those concerns. There's a lot of pent-up desire among many to return to normal life quickly. Count me in that group. But I also realize that the COVID-19 outbreak could continue to be a problem for longer than any of us would like. And the economic toll could be greater and last longer than some expect as well.

These factors weighed on my decision in picking Vertex as my top stock to buy in May. I think that Vertex is practically coronavirus-proof and recession-proof. The company markets drugs that treat the underlying genetic cause of cystic fibrosis (CF).

Because CF can impact lung function, patients really don't want to be diagnosed with COVID-19, which also affects the lungs. The likelihood that Vertex's product sales will fall off significantly because of the pandemic is therefore quite small.

An economic recession won't hurt the biotech's revenue much, either. Insurers will continue to pay for Vertex's drugs and patients will continue taking the drugs regardless of whether the economy is good or bad.

Vertex reported its first-quarter results on Wednesday. Those results included $895 million in sales for a new CF drug, Trikafta.

There are two things that are remarkable about that sales figure. First, the huge sales were generated in the drug's first full quarter on the market. Second, the FDA's approval decision was originally scheduled for March 20, 2020, which would have meant only minimal sales in Q1. But the FDA instead approved Trikafta five months early on Oct. 21, 2019 -- something that's nearly unheard of in the drug industry.

Image source: Getty Images.

Trikafta's commercial success is another key reason why I think so highly of Vertex's prospects. I'm not expecting massive near-term sales growth in the U.S. after the fantastic launch. Vertex CEO ReshmaKewalramani noted in the company's Q1 call that the majority of eligible patients in the U.S. are already taking Trikafta. However, Vertex should win European approval for the drug later this year -- and that will pave the way for tremendous growth.

Also, Vertex plans to file for FDA approval of Trikafta in treating younger CF patients between the ages of six and 11 in the second half of this year. Although this indication won't likely be approved until 2021, it sets the stage for even more growth.

While I think Vertex is a great stock to buy in May, it's not just because of what will happen for the biotech in the coming months or even the next year or two. My view is that Vertex has several exciting longer-term potential catalysts.

The company is leveraging its expertise in CF to target other genetic diseases that are also caused by protein folding issues. Its most promising pipeline candidate in this category is VX-814, which is being evaluated in a phase 2 study for treating alpha-1 antitrypsin deficiency (AATD), a rare genetic disease that affects a similar number of patients worldwide that CF does.

Another of Vertex's clinical programs that appears to be really promising is its collaboration with CRISPR Therapeutics on CTX001. The gene-editing therapy is currently in an early stage study targeting rare blood diseases beta-thalassemia and sickle cell disease. If CTX001 is successful, it could potentially cure both of these diseases.

Speaking of potential cures, Vertex also hopes to advance into clinical testing later this year or at least by early 2021 a gene-editing therapy just might cure type 1 diabetes. Vertex picked up the program with its acquisition of Semma Therapeutics last year. It's still really early, but this is a candidate that couldbe a game-changer.

Image source: Getty Images.

I'm unabashedly a fan of Vertex, but I'll admit that there are two main knocks against the stock. One is its valuation. Shares trade at more than 33 times expected earnings. The other is that the biotech doesn't have any late-stage pipeline candidates. Neither of these issues concerns me all that much, though.

Although Vertex's forward earnings multiple is high, my view is that the company's longer-term growth prospects need to be taken into consideration. The stock's price-to-earnings-to-growth (PEG) ratio, which factors in five years of projected growth, stands at only 0.59. A PEG ratio below 1.0 is usually considered to be an attractive valuation.

Vertex's lack of late-stage programs might be worrisome if the company didn't have a clear pathway to growth over the next several years. But it does have such a pathway. As Trikafta wins additional approvals around the world and for treating younger patients, it should enable Vertex to treat roughly 90% of all CF patients. Winning these approvals and launching the drug for new approved indications will give Vertex plenty of room for growth while its pipeline programs advance.

It's also important to note that Vertex sits on a cash stockpile of $4.2 billion. The company's management team has stated repeatedly that more business development deals are on the way to bolster the pipeline. I'm confident that Vertex will have more growth drivers in place when the time comes that its CF franchise revenue growth begins to taper off.

See the article here:
Here's My Top Stock to Buy in May - The Motley Fool

Nanomedicine Market Size by Top Key Players, Growth Opportunities, Incremental Revenue , Outlook and Forecasts to 2026 – Latest Herald

Global Nanomedicine Market is Segmented by Application, End-Use, Product Type and Region

Global Nanomedicine Market 2020: This is a latest report, covering the current COVID-19 impact analysis on the market. This has led to several changes in market conditions. The rapidly changing market scenario as well as the first and future impact assessment are covered with in the report.

The Nanomedicine Market research report included analysis of various factors that increase market growth. It contains trends, restrictions and drivers that change the market positively or negatively. The Nanomedicine Market Report includes all key factors that affect global and regional markets, including drivers, detention, threats, challenges, risk factors, opportunities, and industry trends. This business research paper provides an in-depth assessment of all critical aspects of the global market in relation to Nanomedicine market size, market share, market growth factor, main suppliers, sales, value, volume, main regions, industry trends, product demand, capacity, cost structure and Nanomedicine market expansion. The report begins with an overview of the structure of the industry chain and describes the industry environment. Then the size of the market and the Nanomedicine forecasts are analyzed by product type, application, end use and region. The report presents the situation of competition on the market between suppliers and the profile of the company. In addition, this report analyzes the market prices and treated the characteristics of the value chain.

For Better Understanding, Download Free Sample Copy Of Nanomedicine Market Report @ https://www.marketresearchintellect.com/download-sample/?rid=201321&utm_source=LHN&utm_medium=888

Why choose us: 24/7 research support | Personalized research service 360 degree approach | 100% customer satisfaction Quality assured

The major players in the market include:

Global Nanomedicine Market: Competitive Landscape

This section of the report lists various major manufacturers in the market. The competitive analysis helps the reader understand the strategies and collaborations that players focus on in order to survive in the market. The reader can identify the players fingerprints by knowing the companys total sales, the companys total price, and its production by company over the 2020-2026 forecast period.

Global Nanomedicine Market: Regional Analysis

The report provides a thorough assessment of the growth and other aspects of the Nanomedicine market in key regions, including the United States, Canada, Italy, Russia, China, Japan, Germany, and the United Kingdom United Kingdom, South Korea, France, Taiwan, Southeast Asia, Mexico, India and Brazil, etc. The main regions covered by the report are North America, Europe, the Asia-Pacific region and Latin America.

The Nanomedicine market report was prepared after various factors determining regional growth, such as the economic, environmental, technological, social and political status of the region concerned, were observed and examined. The analysts examined sales, production, and manufacturer data for each region. This section analyzes sales and volume by region for the forecast period from 2020 to 2026. These analyzes help the reader understand the potential value of investments in a particular country / region.

We Offer up to 30% Discount @ https://www.marketresearchintellect.com/ask-for-discount/?rid=201321&utm_source=LHN&utm_medium=888

Key Benefits for Stakeholders:

The report provides an in-depth analysis of the size of the Nanomedicine world market, as well as recent trends and future estimates, in order to clarify the upcoming investment pockets.

The report provides data on key growth drivers, constraints and opportunities, as well as their impact assessment on the size of the Nanomedicine market.

Porters 5 Strength Rating shows how effective buyers and suppliers are in the industry.

The quantitative analysis of the Nanomedicine world industry from 2020 to 2026 is provided to determine the potential of the Nanomedicine market.

This Nanomedicine Market Report Answers To Your Following Questions:

Who are the main global players in this Nanomedicine market? What is the profile of your company, its product information, its contact details?

What was the status of the global market? What was the capacity, the production value, the cost and the profit of the market?

What are the forecasts of the global industry taking into account the capacity, the production and the value of production? How high is the cost and profit estimate? What will be the market share, supply, and consumption? What about imports and export?

What is market chain analysis by upstream raw materials and downstream industry?

Get Complete Report @ https://www.marketresearchintellect.com/need-customization/?rid=201321&utm_source=LHN&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Nanomedicine Market Size, Nanomedicine Market Trends, Nanomedicine Market Growth, Nanomedicine Market Forecast, Nanomedicine Market Analysis

See the article here:
Nanomedicine Market Size by Top Key Players, Growth Opportunities, Incremental Revenue , Outlook and Forecasts to 2026 - Latest Herald

COVID-19: T cells offer clues to the potential power of Roche’s Actemra – FierceBiotech

The successful activation of T cells is critical to the immune system's ability to clear infections. A new retrospective study from China found that COVID-19 patients had remarkably low T-cell counts in their blood. And they had sky-high levels ofsome pro-inflammatory cytokines such as IL-6which Roches Actemra targets.

Actemra has previously shown promise at controlling potentially life-threatening cytokine storm in COVID-19 patients in China and France, and Roche is running a large phase 3 to confirm its effectiveness in treating patients with COVID-19.

In thestudy from China, published in Frontiers in Immunology, a group of scientists analyzed T-cell counts in 499 COVID-19 patients being treated for the disease in the city of Wuhan. They found a negative correlation between T-cell numbers and cytokines. The team suggested that the novel coronavirus doesnt attack T cells directly, but rather triggers an overproduction of cytokines, which in turn contributes to the depletion and exhaustion of T cells.

FiercePharma Presents the Virtual eRegulatory Operations Summit

Join industry experts and learn how to build and manage cohesive, compliant, and timely electronic submissions through innovative technologies and seamless clinical documentation processes.

The Chinese researchers noticed that about 76% of patients had insufficient T cells, and the level was much lower in those in intensive care. They then examined the concentrations of cytokines from the blood of these patients and found that the levels of TNF-alpha, IL-6 and IL-10 were significantly increased in infected patients. The elevation was even more pronounced in ICU patients.TNF-alpha is known to promote T-cell death, and dysregulated IL-6 has been shown to induce chronic inflammation.

As the patients gradually recovered, their T cell counts improved, while levels of those cytokines dramatically declined. Sothe researchers hypothesize that the depletionof T cells in COVID-19 patients may be the result ofcytokines impedingT-cell survival or proliferation.

Whats more, the T cells that did survive showed signs of exhaustion, with markedly higher expression of immune-inhibitory factors such as PD-1 and Tim-3 on their surface. That was a sign that their functioning was impaired, the researchers reported.

Based on these findings, the team arguedthe secretion of pro-inflammatory cytokines likely does not come from T cells, butthat the cytokine storm may promote the death of the critical immune cells.

RELATED:Reviving tired T cells to improve immuno-oncology treatments

Finding new ways to restore the vigor of immune cells hasbeen of interest in the biomedical research community, notably in oncology. A team at the University of Pennsylvania, for example, found that a protein called TOX in T cells controls the balance of effector T cells and exhausted T cells, suggesting it could be targeted to improve immuno-oncology treatments. And scientists at the La Jolla institute for Immunology recently showed that crippling all three proteins of Nr4a transcription factors could rejuvenate exhausted CAR-T cells to fight solid tumors in mice.

Based on their findings, the Chinese team suggested thatfuture COVID-19 research should focus on identifying more drugs that provide much-needed support toT cells.

We should pay more attention to T cell counts and their function, rather than respiratory function of patients, the studys corresponding author, Yongwen Chenof the Third Military Medical University in China, said in a statement, adding that more urgent, early intervention may be required in patients with low T lymphocyte counts.

Read the original here:
COVID-19: T cells offer clues to the potential power of Roche's Actemra - FierceBiotech

T Cell Counts and Cytokine Storms May Hold Key to Effective COVID-19 Treatment – Technology Networks

Cytokine storms may affect the severity of COVID-19 cases by lowering T cell counts, according to a new study published in Frontiers in Immunology. Researchers studying coronavirus cases in China found that sick patients had a significantly low number of T cells, a type of white blood cell that plays a crucial role in immune response, and that T cell counts were negatively correlated with case severity.Interestingly, they also found a high concentration of cytokines, a protein that normally helps fight off infection. Too many cytokines can trigger an excessive inflammatory response known as a cytokine storm, which causes the proteins to attack healthy cells. The study suggests that coronavirus does not attack T cells directly, but rather triggers the cytokine release, which then drives the depletion and exhaustion of T cells.

The findings offer clues on how to target treatment for COVID-19, which has become a worldwide pandemic and a widespread threat to human health in the past few months. We should pay more attention to T cell counts and their function, rather than respiratory function of patients, says author Dr. Yongwen Chen of Third Military Medical University in China, adding that more urgent, early intervention may be required in patients with low T lymphocyte counts.

Chen says he and his co-authors became interested in examining T cells when they noticed that many of the patients they treated for COVID-19 had abnormally low numbers of lymphocytes, a type of white blood cell that includes T cells. Considering T cells central role of response against viral infections, especially in the early stage when antibodies are not boosted yet, we took the T cells as our focal point, says Chen.

Authors examined 522 patients with coronavirus along with 40 healthy controls. All patients studied were admitted to two hospitals in Wuhan, China between December 2019 and January 2020, and ages ranged between 5 days and 97 years old. Of the 499 patients who had their lymphocytes recorded, 76% had significantly low total T cell counts. ICU patients had significantly lower T cell counts compared with non-ICU cases, and patients over the age of 60 had the lowest number of T cells.

Importantly, the T cells that did survive were exhausted and could not function at full capacity. Not only does this have implications for COVID-19 patient outcomes, but T cell exhaustion leaves patients more vulnerable to secondary infection and calls for scrupulous care.

Chen says that future research should focus on finding finer subpopulations of T cells in order to discover their vulnerability and effect in disease, along with identifying drugs that recover T cell numbers and boost function. Authors say that Tocilizumab is an existing drug that may be effective, but that it needs to be investigated in the context of coronavirus. Antiviral treatments, such as Remdesivir, may also prevent the progression of T cell exhaustion, but all future treatments will require further study.

In the meantime, this new research deepens our understanding of how the novel coronavirus affects the body and it indicates ways to lessen its impact.ReferenceDiao et al. (2020). Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Frontiers in Immunology. DOI: https://doi.org/10.3389/fimmu.2020.00827

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

The rest is here:
T Cell Counts and Cytokine Storms May Hold Key to Effective COVID-19 Treatment - Technology Networks

New clues on how to treat COVID-19 from T cell counts – The Nation

ISLAMABAD-Cytokine storms may affect the severity of COVID-19 cases by lowering T cell counts, according to a new study published. Researchers studying coronavirus cases in China found that sick patients had a significantly low number of T cells, a type of white blood cell that plays a crucial role in immune response, and that T cell counts were negatively correlated with case severity. Interestingly, they also found a high concentration of cytokines, a protein that normally helps fight off infection. Too many cytokines can trigger an excessive inflammatory response known as a cytokine storm, which causes the proteins to attack healthy cells. The study suggests that coronavirus does not attack T cells directly, but rather triggers the cytokine release, which then drives the depletion and exhaustion of T cells.

The findings offer clues on how to target treatment for COVID-19, which has become a worldwide pandemic and a widespread threat to human health in the past few months. We should pay more attention to T cell counts and their function, rather than respiratory function of patients, says author Dr. Yongwen Chen of Third Military Medical University in China, adding that more urgent, early intervention may be required in patients with low T lymphocyte counts.

Go here to read the rest:
New clues on how to treat COVID-19 from T cell counts - The Nation

I want to help hundreds of thousands: Former BYU star Kyle Collinsworth on quest to help people get healthy – Deseret News

PROVO When he was a sophomore at BYU, Kyle Collinsworths passing and rebounding skills, as well as his overall court awareness, made him one of the top college basketball players in the country.

But in terms of his diet, he was a typical college student. Eating healthy wasnt a big priority.

Id eat Taco Bell at 1 in the morning, he recalled. I ate terrible candy and sugar all the time.

But that all changed at the end of his sophomore season.

Six years ago, in the second half of the West Coast Conference Tournament championship game against Gonzaga, the Cougar star landed awkwardly on his right leg and remained on the floor at Orleans Arena in Las Vegas for several minutes, writhing in pain before he was helped to the locker room.

The Cougars ended up losing to the Zags and when the team returned to Provo, an MRI revealed that Collinsworth had suffered a torn anterior cruciate ligament in his right knee and he was unable to compete in the NCAA Tournament the following week. A long and grueling rehab period awaited.

Park City surgeon Vernon Cooley performed the surgery on Collinsworths knee. The prognosis was for Collinsworth to return in 10 months. But the Provo native wanted to return sooner. Cooley advised Collinsworth that if he improved his nutrition, it could help him possibly return in six months and be ready for the first game the following November.

Collinsworth, who had returned from a mission for The Church of Jesus Christ of Latter-day Saints in Russia less than a year before the injury, took that counsel to heart.

I started drinking green smoothies, he said, and after a few weeks of having a smoothie every day, my desire to have fast food just went away.

Grid View

The timing and severity of the injury cast doubt on whether Collinsworth would be able to return that soon, let alone play at a high level as a junior.

Not only was Collinsworth on the floor in the season opener against Long Beach State that November, but he also ended up recording the programs first triple-double in 26 years a month later. He went on to become the NCAAs triple-double king, compiling 12 career triple-doubles, an NCAA record, over his final two seasons.

Collinsworths ability to return seemingly seamlessly from ACL surgery was, at first, somewhat stunning to observers. He credits many factors to his recovery, including healthy eating.

That was a huge reason why I was able to come back so fast and recover so quickly. From that whole process, I learned a lot of strategies that helped with eating healthy, he said. I feel better and Ive seen success with it not just with my body and basketball but with my life as a whole.

Now, as a guard for the Salt Lake City Stars of the NBA G League, that lifestyle change that he maintains today has also grown into an altruistic cottage industry.

While he has fully embraced the power of nutrition and positive health habits, he wants to help others become the best version of themselves by offering motivation and challenges for people to get healthy via Twitter, newsletters and e-books.

Two of his e-books are titled, Born to be Strong: A Guide to Reclaiming Your Natural Strong Body and The Power of Food: Body, Mind, and Spirit. They feature recipes, video tutorials and food charts. To receive his newsletter and learn more, follow him on Twitter: https://twitter.com/bigrussia5.

What Collinsworth shares isnt a diet. Its a lifestyle. And its about simplicity combined with consistency.

Its been six-plus years now and I keep learning more and more, he said. Ive really been blessed with the power of eating healthy and exercise on my body, mind and spirit. Ive been on both sides, so I get it.

The information he shares, gleaned from a massive amount of reading, as well as empirical research, is free.

At BYU, Collinsworth ranks No. 13 all-time in scoring, No. 2 in rebounding, and No. 1 in assists. But this might be his most important assist.

I always comment with people and answer questions (on Twitter). All the monthly guides are free. Im just trying to help people reach their potential, he said. Thats one area Im passionate about healthy eating and exercise. I want to take what Ive learned and help as many people as I can to get healthy. Thousands have signed up for my newsletter. I dont know the exact number. But I want to help hundreds of thousands.

Among those that he has helped include former NBA superstar Dirk Nowitzki, who was Collinsworths teammate when he played with the Dallas Mavericks. Nowitzki was dealing with a foot injury and Collinsworth helped him with some meal stuff. Hes also helped Doug McDermott of the Indiana Pacers.

But Collinsworth is just as passionate about helping those who arent professional athletes average people that may struggle with maintaining a healthy weight or want to feel better about themselves.

And right now, with the coronavirus pandemic keeping people inside and altering their routines, this is the perfect opportunity for people to make changes in their lives, Collinsworth said.

Theres never been a better time to focus on your health than right now. I call this a compound moment. You are either going to come out of this better or worse. Theres so much idle time and time to be with your thoughts. Its a crucial time to do things youve always wanted to do, focus on things you know you need to do and put your head down and go to work and focus on one thing at a time.

In 2015, Collinsworth married Shea Martinez, an an All-American 800-meter runner on BYUs track team who continues to compete. When they met at BYU, she wasnt too concerned about her diet.

She saw what I was doing and joined it. She saw the results and felt good, Kyle said. I was probably 6-7 months eating healthy when I met her. She jumped right in. Its a huge part of our lives. We love making dinner together. Its a good time for us to talk. We prepare the food, eat it and clean it up together. Its always time set aside for us.

Collinsworth understands the obstacles that prevent people from living a healthy lifestyle.

My Rule No. 1 is to avoid too much too soon. Thats the biggest obstacle. If you were to start a diet today, and you wrote down in detail right now, I would guess for most people, they could no longer eat 95% of the food that they eat now, he said. What happens is, all the sudden the healthy food theyre supposed to be eating becomes stressful and negative. And the food theyre not supposed to be eating becomes the hero that they crave and miss. Its all because youve tried to do too much too soon. Thats everyones biggest mistake. People think you have to be doing all of this crazy stuff, whether its running five miles or eating a perfect diet instead of simply adding a green smoothie every day. What I discovered is, when you focus on adding one thing at a time, it really compounds. When you add more good, the bad naturally goes away with time.

Collinsworth encourages people to add one healthy habit at a time to reach their goals.

Part of what I try to teach people now is the power of focusing on one thing at a time. I call it subtraction by addition. I went from green smoothies and then I started having salads every day then I started riding a bike. I started adding good habits one at a time, he said. It was cool to look back and see that. So many things left my life with less friction and stress. Thats what Im trying to teach people now. Getting healthy doesnt have to be stressful. The minute it feels stressful, and you feel friction, you create a negative association to eating healthy and it almost makes it impossible to do. Its really a big mental game, eating healthy. I learned that along my journey with my ACL.

What you eat now impacts your future, Collinsworth said, even if youre not an elite athlete.

What I tell people is, eat for the next decade. If youre in your 20s, eat for your 30s. If youre in your 30s, eat for your 40s, he said.
In college, I could get away with eating Taco Bell. People tell me, You just eat healthy because youre a professional athlete. But professional athletes dont eat healthy, most of them. Thats the reality. Ive been in several NBA locker rooms. Thats not the case. I see the impact. It can cut careers shorter. Its for our future bodies. You cant take your health for granted.

Collinsworth has created a One Habit At A Time program to help others.

Every month, I pick a habit and I create a calendar for people to follow along. For January, it was intermittent fasting, he said. For February, it was green smoothies. March was a walking guide. April (was) a push-up guide. Im just trying to help people focus on one thing at a time and keeping things simple. If you think about it, if you were to add one good habit every month for the whole year, youd come away with 12 good habits. Im trying to help people create a healthy lifestyle. Im not a big fan of diets because its restriction and frustration. It creates a negative association with what youre trying to do. Eating healthy and exercising is one way to help us reach our true potential. If we want to be the best version of ourselves, that has to include healthy eating and exercise. Its one way and there are many ways.

Collinsworths professional career has brought him back to his home state with the Stars, which has been a blessing for him and his family.

There have been some ups and down, being in and out of the NBA, he said. But this years been incredible, to be home and playing in front of family again. Shea was home this year, training in Provo. Its been a very different year with everyone going on. But its been one of my favorites to be able to be home. With the virus, its a chance to focus on what matters most.

At BYU, Collinsworth was known for racking up big numbers in a variety of categories. These days, hes looking to add to the number of people he can help enjoy a more fulfilling lifestyle, like the one hes discovered.

Read more:
I want to help hundreds of thousands: Former BYU star Kyle Collinsworth on quest to help people get healthy - Deseret News